NEW YORK — LumiraDx said on Thursday that it has received CE marking for its point-of-care SARS-CoV-2 & Flu A/B Antigen Test.
The microfluidic immunofluorescence assay is designed for the simultaneous detection and differentiation of SARS-CoV-2, influenza A, and influenza B viral antigen in nasal swab specimens. It runs on the LumiraDx platform and provides results within 12 minutes.
Last month, UK-based LumiraDx — which went public on the Nasdaq in April — reported surging third quarter revenues on strong sales of its of test strips for its COVID Ag SARS-CoV-2 antigen test.